Clinical Trials | April 04, 2024
Evonik unveils latest global trial results MetAMINO
Reconfirms a relative bioavailability of 65 percent and significant savings when using DL-methionine
Reconfirms a relative bioavailability of 65 percent and significant savings when using DL-methionine
Grand opening of the joint venture between Evonik China and Shandong Vland Biotech in Qingdao, China
More than 10,000 scientific publications containing EUDRAGIT
New institute brings together Evonik’s most advanced biotech platform and a global network of evaluation labs
Commercialization of rPEG lipids designed to improve immunogenicity profile for nucleic acid delivery
High-quality baobab oil sourced in collaboration with UNCCD and the Great Green Wall Initiative
PhytoSquene now available for clinical and commercial use
Three block copolymers added to RESOMER portfolio of bioabsorbable polymers
Seamless transition from preclinical to first-in-human trials with EUDRACAP platform technology
Evonik China and Shandong Vland Biotech agreed to build a joint venture to expand their presence in gut health solutions products for farm animals globally
Subscribe To Our Newsletter & Stay Updated
